Unknown

Dataset Information

Immune checkpoint inhibitors for cancer and venous thromboembolic events.


ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) are widely used cancer treatments. There are limited data on the risk for developing venous thromboembolism (VTE) among patients on an ICI.

Methods

This was a retrospective study of 2854 patients who received ICIs at a single academic centre. VTE events, defined as a composite of deep vein thrombosis or pulmonary embolism, were identified by individual chart review and blindly adjudicated using standard imaging criteria. A self-controlled risk-interval design was applied with an 'at-risk period' defined as the two-year period after and the 'control period', defined as the two-year before treatment. The hazard ratio (HR) was calculated using a fixed-effect proportional hazards model.

Results

Of the 2854 patients, 1640 (57.

SUBMITTER: Gong J 

PROVIDER: S-EPMC9010482 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature